Chronic GVHD (cGVHD) is an important complication of allogeneic hematopoietic cell transplantation (HCT). As preemptive therapy might be efficacious if administered early post transplant, we set out to determine whether cGVHD can be predicted from the serum level of a biomarker on day 7 or 28. In a discovery cohort of 153 HCT recipients conditioned with BU, fludarabine and rabbit antithymocyte globulin (ATG), we determined serum levels of B-cell-activating factor, vascular endothelial growth factor, soluble TNF-a receptor 1, soluble IL2 receptor a, IL5, IL6, IL7, IL15, g-glutamyl transpeptidase, cholinesterase, total protein, urea and ATG. Patients with low levels of IL15 (o30.6 ng/L) on day 7 had 2.7-fold higher likelihood of developing significant cGVHD (needing systemic immunosuppressive therapy) than patients with higher IL15 levels (Po0.001). This was validated in a validation cohort of 105 similarly-treated patients; those with low IL15 levels had 3.7-fold higher likelihood of developing significant cGVHD (P ¼ 0.001). Low IL15 was not associated with relapse; it trended to be associated with acute GVHD and was associated with low infection rates. In conclusion, low IL15 levels on day 7 are predictive of cGVHD, and thus could be useful in guiding preemptive therapy.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is often curative for hematologic malignancies and benign disorders of hematopoiesis. Unfortunately, about one half of HCT recipients develop GVDH (cGVHD) disease, the most significant predictor of late non-relapse mortality and poor quality of life. 1, 2 The pathogenesis of cGVHD is poorly understood. Given that it can be prevented by depleting T cells from the graft, it is generally assumed that donor T cells contained in the graft have a role in at least initiating cGVHD. However, in addition to donor T cells reacting against host antigens, immune dysregulation in general (including reactions against both host and donor antigens) has a role in the pathogenesis. 3, 4 Treatment of clinically significant cGVHD (extensive per Seattle criteria 5 or moderate to severe per NIH Consensus criteria 6 ) consists of corticosteroids with or without other immunosuppressive drugs. 7, 8 The treatment is far from optimal as it is toxic and rarely results in sustained complete response. Prophylaxis of cGVHD using T-cell depletion ex vivo (for example, by graft enrichment for CD34 cells) or in vivo (for example, using alemtuzumab or polyclonal anti-T-cell antibodies like rabbit antithymocyte globulin (ATG)) is more efficacious than treatment. [9] [10] [11] [12] [13] [14] [15] However, the prophylaxis has side effects (for example, viral infections 16 ). Therefore, it would be desirable to give prophylaxis or preemptive therapy only to patients at high risk of developing cGVHD. 17 Known predictive factors of cGVHD include older donor, older recipient, female donor (or donor-recipient gender combination other than male-male), donor-recipient unrelatedness and HLA mismatch, and blood stem cells as opposed to a marrow graft. 18 However, these known predictive factors cannot reliably distinguish between patients who will vs those who will not develop cGVHD.
Thus new predictive biomarkers are needed. 19 We focused on potential biomarkers that can be measured in serum early post transplant, as it has been recently shown that ATG administered early post transplant can prevent development of cGVHD. 20 Potential biomarkers evaluated in this study included the cytokines B-cell activating factor (BAFF), vascular endothelial growth factor, soluble TNF-a receptor 1, soluble IL2 receptor a, IL5, IL6, IL7 and IL15, and g-glutamyl transpeptidase, cholinesterase, total protein, urea and ATG levels. The cytokines were chosen as their levels have been reported to be associated with cGVHD and/or acute GVHD (aGVHD being a strong predictor of cGVHD). [21] [22] [23] [24] [25] [26] [27] [28] [29] g-glutamyl transpeptidase, cholinesterase, total protein and urea were chosen as their levels early post transplant had been reported to predict non-relapse mortality 20, 30 and cGVHD is a major contributor to non-relapse mortality. ATG was chosen as its levels early post transplant have been reported to predict aGVHD and/or cGVHD. 31, 32 
PATIENTS AND METHODS
See Supplementary material and Table 1 . Briefly, the discovery cohort consisted of 153 patients and the validation cohort of 105 patients (recipients of first allogeneic HCT). Conditioning was typically with fludarabine (250 mg/m 2 ), BU (B12.8 mg/kg), TBI (4 Gy), rabbit ATG (Thymoglobulin, 4.5 mg/kg), and additional GVHD prophylaxis was with MTX and CYA. 33, 34 Blood was drawn on approximately days 7 and 28. Serum levels of cytokines were determined using sandwich ELISA. cGVHD was graded as none, not needing systemic immunosuppression (roughly corresponding to limited cGVHD per Seattle criteria 5 or mild cGVHD per NIH criteria 6 ), and needing systemic immunosuppression (roughly corresponding to extensive cGVHD by Seattle criteria or moderate to severe cGVHD by NIH criteria). Throughout this paper, 'cGVHD' refers to cGVHD needing systemic immunosuppression (both no cGVHD and cGVHD not needing systemic immunosuppression are considered as cGVHD absent), unless otherwise specified. The significance of the association between each serum cytokine or another biomarker level and cGVHD was first evaluated by univariate analysis in the discovery cohort. Associations that appeared significant by the univariate analysis were tested by multivariate analyses in the discovery cohort. Associations significant by the multivariate analyses were then tested by the same statistical methods in the validation cohort. Associations significant by multivariate analyses in both discovery and validation cohorts were considered valid.
RESULTS

Discovery cohort
In univariate analysis, compared with patients who did not develop cGVHD, those who developed cGVHD had significantly lower levels of day 7 IL15 (P ¼ 0.029) (Figure 1, top) , higher levels of day 7 cholinesterase (P ¼ 0.041), lower levels of day 28 BAFF (P ¼ 0.033), lower levels of day 28 IL6 (P ¼ 0.006) and lower levels of day 28 IL7 (P ¼ 0.037) ( Table 2) .
In multivariate analysis, IL15 levels on day 7 above 30.6 ng/L were associated with a low risk of developing cGVHD (relative risk (RR) ¼ 0.37; Po0.001) ( Table 2 and Figure 2 , top). Cholinesterase levels on day 7 above 6.3 U/L were associated with a high risk of cGVHD (RR ¼ 2.62; P ¼ 0.004). Day 28 levels of BAFF above 12.9 ng/L, IL6 above 4.78 ng/L and IL7 above 5.82 ng/L were associated with a low risk of cGVHD (RR ¼ 0.55, 0.55 and 0.55, and P ¼ 0.003, 0.013 and 0.041, respectively).
Validation Cohort
In univariate analysis, compared with patients who did not develop cGVHD, those who developed cGVHD had significantly Good risk disease was defined as acute leukemia in first remission, chronic myelogenous leukemia in first chronic or accelerated phase, myelodyplastic syndrome if o5% marrow blasts of aplastic anemia. All other diseases/disease stages were considered poor risk.
Matched unrelated donor (n ¼ 52 for discovery cohort, n ¼ 52 for validation cohort), matched cousin/parent (n ¼ 1 for discovery cohort, n ¼ 1 for validation cohort), mismatched unrelated donor (n ¼ 22 for discovery cohort, n ¼ 10 for validation cohort), or mismatched sibling (n ¼ 3 for discovery, n ¼ 0 for validation cohort). In multivariate analysis, only IL15 levels were associated with cGVHD. Specifically, IL15 levels on day 7 above 30.6 ng/L were associated with a low risk of cGVHD (incidence rate ratio ¼ 0.27; P ¼ 0.001) ( Table 2 and Figure 2 , bottom).
Onset of cGVHD and IL15 cGVHD can be preceded by grade 2-4 aGVHD, or can develop in the absence of preceding grade 2-4 aGVHD (de novo cGVHD). In multivariate analysis, combining both discovery and validation cohorts, IL15 levels on day 7 above 30.6 ng/L were associated with a low risk of developing both de novo cGVHD (RR ¼ 0.32, Po0.001) as well as cGVHD preceded by aGVHD (RR ¼ 0.28, P ¼ 001).
Sensitivity and specificity of day 7 IL15 levels for cGVHD When combining both discovery and validation cohorts, day 7 IL15 level under 30.6 ng/L predicted cGVHD with the sensitivity of 64.1%, the specificity of 75.0%, positive predictive value of 60.3% and negative predictive value of 77.9%. This analysis, together with all above analyses, was restricted only to patients evaluable for cGVHD, omitting patients who were unevaluable for cGVHD, typically due to relapse or post transplant lymphoproliferative disorder prior to day 100. However, for the potential future use of low day 7 IL15 level as a trigger for preemptive immunosuppressive therapy, it is important to consider patients both evaluable and unevaluable for cGVHD. If most of the patients unevaluable for cGVHD had low day 7 IL15 level, using preemptive immunosuppressive therapy could be dangerous as it could increase risk of relapse or infections (including post transplant lymphoproliferative disorder). As shown in Figure 1 , the patients unevaluable for cGVHD had significantly higher day 7 IL15 levels than patients who developed cGVHD (Po0.001 in the discovery cohort and P ¼ 0.005 in the validation cohort). When including all patients (both evaluable and unevaluable for cGVHD and both discovery and validation cohorts), the sensitivity of day 7 IL15 levels under 30.6 ng/L was 64.1%, the specificity was 76.1%, the positive predictive value was 54.7% and the NPV was 82.4%.
IL15 levels on day 7 and outcomes other than cGVHD For the consideration of low day 7 IL15 level as a trigger for preemptive immunosuppressive therapy, it is important to evaluate whether low IL15 is a biomarker of not only cGVHD, but also relapse or infections, because if that was the case, the preemptive immunosuppressive therapy would be relatively contraindicated. The preemptive immunosuppressive therapy would also be relatively contraindicated if low IL15 was a biomarker of improved survival. Conversely, the preemptive immunosuppressive therapy would likely be of higher impact if low IL15 was a biomarker of not only cGVHD, but also aGVHD. So we assessed potential association between day 7 IL15 level and relapse, infections, survival and aGVHD. Patients both evaluable and unevaluable for cGVHD and from both discovery and validation cohorts were included into the analyses. Patients who relapsed did not have a significantly lower IL15 levels than patients who did not relapse (median 33.2 vs 36.7 ng/L, P ¼ 0.96 (Mann-Whitney-Wilcoxon test, excluding patients who had nonrelapse death)). For infections, there was a positive (not negative) correlation between IL15 levels and day 7-83 rates (densities) of any infections (definite or presumed), definite infections, viral infections, bacterial infections or fungal infections (Spearman's rank correlation coefficients were 0.30, 0.31, 0.23, 0.13 and 0.16, respectively, and P-values were o0.001, o0.001, 0.001, 0.064 and 0.024, respectively). There was also positive correlation between IL15 levels and day 7-364 rates of any, definite, viral, bacterial or fungal infections (Spearman's rank correlation coefficients were 0.29, 0.31, 0.24, 0.18 and 0.17, and P-values were o0.001, respectively, o0.001, 0.001, 0.011 and 0.017, respectively). Patients who died did not have a significantly lower IL15 levels than patients who did not die (median 39.4 vs 36.6 ng/L, P ¼ 0.36 (Mann-Whitney-Wilcoxon test)). Patients who developed aGVHD had significantly lower IL15 levels than patient who did not develop aGVHD (median 30.5 vs 40.0 ng/L, P ¼ 0.03 (MannWhitney-Wilcoxon test)). Thus, there was no association of low IL15 levels with high likelihood of relapse, infections or survival, and there was a trend (significant only when combining discovery-validation cohorts) toward association with high likelihood of aGVHD.
Association between biomarker levels and any grade cGVHD In above analyses, we categorized cGVHD not needing systemic therapy as no cGVHD. This was because patients with mild/limited GVHD are known to have the highest leukemia-free survival, 33, 34 so it might be inappropriate to offer them preemptive immunosuppressive therapy. Nevertheless, for the understanding of cGVHD pathogenesis, it is important to compare patients with no cGVHD vs any grade cGVHD (both needing and not needing systemic immunosuppressive therapy). It is also important to exclude from such analysis patients with late aGVHD or with insufficient information for categorization into cGVHD vs late aGVHD. 6 We did these analyses, after excluding 13 patients with late aGVHD or insufficient information on cGVHD vs late aGVHD, combining discovery and validation cohorts, and including aGVHD among covariates. The reason for including aGVHD among covariates was that we wished to determine direct association between biomarker level and cGVHD rather than indirect association (biomarker level being associated with aGVHD, which predisposes to cGVHD). As shown in Table 3 , any grade cGVHD was associated with low levels of day 7 IL15 and low levels of day 7 and day 28 ATG. It was also associated with high levels of IL2Ra and TNFaR1 on day 7, suggesting that T-cell activation and inflammation in the first week after HCT have a role in the pathogenesis of cGVHD (which typically manifests at X3 months after HCT). Any grade cGVHD was also associated with low levels of BAFF, IL6 and IL7 on day 28.
Towards the mechanism of the association between low day 7 IL15 and cGVHD IL15 is a homeostatic cytokine for CD8 T-cell and NK cell counts. 35, 36 Thus, we hypothesized that a low day 7 IL15 level could be a surrogate of slow reconstitution of CD8 T cells or NK cells, which could be a result of a high ATG level. If this was true, we would expect a positive correlation between IL15 levels and CD8 T-cell or NK cell counts, and negative correlation between IL15 and ATG levels. CD8 T-cell and NK cell counts (measured as described in Bosch et al. 37 ) from day 28 (unfortunately not from a time point closer to day 7) were available to us for 62 discovery cohort patients. There was no significant correlation between day 7 IL15 levels and the counts of NK cells. However, there was a significant negative correlation between day 7 IL15 levels and the counts of CD8 T cells (Spearman's correlation coefficient r ¼ À 0.47, Po0.0001) (Figure 3 ). This suggests that the low IL15 level is a surrogate for expansion of total CD8 T cells. To evaluate whether IL15 levels might be related to ATG levels, we determined whether there was a correlation between day 7 IL15 levels and day 7 ATG levels using discovery cohort patients (as both biomarkers were measured in this cohort). There was a highly significant correlation between the IL15 and ATG levels (Spearman's correlation coefficient r ¼ 0.58, Po0.0001) (Figure 3 ). This suggests that low quantity of CD8 T cells, which stimulates homeostatic increase in IL15 level, is a result of ATG killing CD8 T cells or inhibiting their expansion.
DISCUSSION
Overall, we have found and subsequently validated that low serum IL15 levels on day 7 are associated with future chronic GVHD. This represents the first biomarker of cGVHD measured early post transplant, that is, at the time when the risk of developing cGVHD may be reduced over twofold using ATG, at least in patients who received ATG also during conditioning. 20 The mechanism of low IL15 level predisposing HCT recipients to cGVHD is not clear. One of the following three mechanisms might apply:
1. IL15 is a homeostatic cytokine for CD8 T cells and NK cells (enhancing their proliferation and survival). 35, 36 Thus, it is possible b Cutoff for or dividing patients into groups with high and low levels determined based on receiver operating characteristic curves as the cutoff yielding maximum sum of sensitivity and specificity. The cutoff levels for IL15, BAFF, IL6 and IL7 are expressed in ng/L and for cholinesterase in U/L. c Multivariate analysis RR for the group with high over the group with low levels. Incidence RR is given if Poisson regression was used. Multivariate analysis P-value. Only associations with multivariate Po0.005 in discovery cohort were validated.
IL15 levels predict cGVHD LM Pratt et al that low IL15 level is a surrogate for expansion of CD8T cells or NK cells, including alloreactive (donor-anti-host) cells.
2. IL15 can upregulate PD1 on T-cells and PD1 ligands on antigen-presenting cells.
38 PD1 and PD1L interaction inhibits T-cell activation, proliferation and acquisition of effector functions, which can contribute to tolerance induction. 39 Thus, theoretically, in the HCT recipients with low IL15, PD1 or PD1L may not be upregulated, which may abrogate tolerance induction and promote GVHD.
3. Donor NK cells can eliminate host dendritic cells, 40 potent stimulators of alloreactive T cells. 41 The NK cell-mediated elimination of host dendritic cells may be enhanced by IL15. 42 Thus, theoretically, in the HCT recipients with low IL15, NK cells many not be sufficiently stimulated to eliminate the GVHDpromoting host dendritic cells.
Given the negative correlation between IL15 levels and CD8 T-cell counts (Figure 3) , we favor mechanism No. 1. As CD8 T cells are usually undetectable on day 7 in blood, 37 the low IL15 level may be a surrogate of expansion of total body CD8 T cells.
A strength of our study was the use of a discovery-validation cohort design. This makes the positive finding of association of low IL15 with cGVHD well substantiated. On the other hand, the rigorous design makes it possible that true associations between some of the studied biomarkers and cGVHD may have been missed.
Two limitations of our study need to be emphasized: (1) use of unconventional cGVHD definition (lumping cGVHD with late aGVHD) and grading, and (2) inclusion of only patients treated homogeneously at a single institution.
The lumping of cGVHD (classic cGVHD and overlap syndrome) with late aGVHD and grading of cGVHD as treated/untreated with systemic immunosuppressive therapy were used for two reasons.
(1) Information in patient charts was not always complete for unequivocal categorization of post-day 100 GVHD as acute or chronic and, if chronic, for grading it as mild, moderate or severe per NIH Consensus criteria. 6 (2) An important candidate drug for preemptive therapy for cGVHD is ATG, which may prevent not only cGVHD but also late aGVHD. The reason we think so is that ATG is known to prevent aGVHD in general, 12, 13, 20, 43, 44 and because in the study showing benefit of preemptive ATG on cGVHD, 20 cGVHD was defined as post-day 100 GVHD, thus presumably including late aGVHD.
The inclusion of patients treated with myeloablative BU þ fludarabine þ ATG þ CYA þ MTX conditioning/GVHD prophylaxis at a single institution creates concern about whether low IL15 would predict cGVHD when using other conditioning/GVHD prophylaxis at other institutions. We suspect that this concern is valid, as in the studies of Thiant et al., 22, 24 compared with patients without aGVHD, median day 14 or 30 IL15 levels in patients developing aGVHD were significantly higher. Contrary to that, in our study, median day 7 and day 28 IL15 levels in patients developing aGVHD were non-significantly lower. Also, in one of the studies of Thiant et al., 22 low IL15 was associated with relapse; patients who relapsed had significantly lower median IL15 levels on day 14 compared with patients who did not (21 vs 40 ng/L, P ¼ 0.02). In our study median IL15 levels in patients who did and did not relapse were similar (33.2 vs 36.7 ng/L on day 7, P ¼ 0.96, and 3.0 vs 3.2 ng/L on day 28, P ¼ 0.98). The major difference between the treatment of Thiant's and our patients was that ATG was not used in most Thiant's patients whereas it was used in all our patients. Moreover, we found a highly significant correlation between IL15 and ATG levels ( Figure 3) . Collectively, the association between low IL15 levels and GVHD may be valid for only ATG-conditioned patients. Perhaps, in patients in whom ATG successfully prevents GVHD, ATG kills or inhibits the proliferation of CD8 T cells, which stimulates homeostatic production of IL15. As high ATG and high IL15 levels appear to have both anti-GVHD and pro-viral effects 16, 32 (see Results), the homeostatic production of IL15 may be stimulated by low numbers of both alloreactive and antiviral CD8 T cells.
How ATG, given peritransplant, prevents cGVHD, [13] [14] [15] 20, 31, 44, 45 which typically develops at X3 months post transplant, has been a mystery. The correlation between ATG and IL15 levels and the inverse correlation between IL15 levels and CD8 T-cell counts ( Figure 3 ) and the published inverse correlation between day 7 or 28 ATG levels and day 28 CD8 T-cell counts 37 suggest that ATG kills or prevents expansion of CD8 T cells, some of which (alloreactive CD8 T cells?) may stimulate cGVHD. The importance of peritransplant events in ATG-conditioned patients for development of cGVHD is further supported by the association between high IL2Ra/TNFaR1 levels on day 7 and cGVHD, independent of aGVHD ( Table 3) . Research into cGVHD pathogenesis has so far focused on immune alterations at the time of cGVHD diagnosis. The published observations on peritransplant ATG influencing cGVHD and our results presented here suggest that the pathogenesis of cGVHD may start already in the first post transplant week.
Our results might lead in the future to a clinical trial using patients who have received ATG-conditioned allogeneic HCT. Patients at high risk of cGVHD would be identified using IL15 levels, ideally in combination with another biomarker that would jointly predict cGVHD with 480% sensitivity and 480% specificity. Preemptive immunosuppressive therapy (for example, ATG 20 or prolonged administration of calcineurin inhibitor) would then be administered to patients at high risk of developing cGVHD. It would be tested whether this leads to lower rates of cGVHD, which could result in improved survival or quality of life. The lack of association of low IL15 levels with high relapse or high infection rates and the trend toward association of low IL15 levels with aGVHD are reassuring from the point of view that the preemptive immunosuppressive therapy would not be given to patients particularly susceptible to relapse or infections and would possibly be given to patients who could benefit from reduced risk of not only cGVHD but also aGVHD. Figure 3 . Negative correlation between day 7 IL15 levels and day 28 CD8 T-cell counts (r ¼ À 0.47, Po0.0001) (top), and positive correlation between day 7 IL15 levels and day 7 ATG levels (r ¼ 0.58, Po0.0001) (bottom). CD8 T-cell counts of o1 Â 10 6 /L were arbitrarily assigned a value of 1 Â 10 6 /L. A linear trendline is displayed in each plot.
